Department of Cardiology, Concord Repatriation General Hospital, University of Sydney, Sydney, Australia.
Int J Cardiol. 2013 Jul 31;167(2):374-7. doi: 10.1016/j.ijcard.2011.12.096. Epub 2012 Jan 23.
Cardiovascular complications are important causes of morbidity and mortality in patients undergoing elective non-cardiac surgery, with adverse cardiac outcomes estimated to occur in approximately 4% of all patients. Anti-platelet therapy withdrawal may precede up to 10% of acute cardiovascular syndromes, with withdrawal in the peri-operative setting incompletely appraised.
The aims of our study were to determine the proportion of patients undergoing elective non-cardiac surgery currently prescribed anti-platelet therapy, and identify current practice in peri-operative management. In addition, the relationship between management of anti-platelet therapy and peri-operative cardiac risk was assessed.
We evaluated consecutive patients attending elective non-cardiac surgery at a major tertiary referral centre. Clinical and biochemical data were collected and analysed on patients currently prescribed anti-platelet therapy. Peri-operative management of anti-platelet therapy was compared with estimated peri-operative cardiac risk.
Included were 2950 consecutive patients, with 516 (17%) prescribed anti-platelet therapy, primarily for ischaemic heart disease. Two hundred and eighty nine (56%) patients had all anti-platelet therapy ceased in the peri-operative period, including 49% of patients with ischaemic heart disease and 46% of patients with previous coronary stenting. Peri-operative cardiac risk score did not influence anti-platelet therapy management.
Approximately 17% of patients undergoing elective non-cardiac surgery are prescribed anti-platelet therapy, the predominant indication being for ischaemic heart disease. Almost half of all patients with previous coronary stenting had no anti-platelet therapy during the peri-operative period. The decision to cease anti-platelet therapy, which occurred commonly, did not appear to be guided by peri-operative cardiac risk stratification.
心血管并发症是非心脏择期手术患者发病率和死亡率的重要原因,约 4%的所有患者发生不良心脏事件。多达 10%的急性心血管综合征可能在抗血小板治疗停药前发生,而围手术期的停药情况尚未完全评估。
本研究旨在确定目前接受择期非心脏手术的患者中使用抗血小板治疗的比例,并确定围手术期管理的现状。此外,还评估了抗血小板治疗管理与围手术期心脏风险之间的关系。
我们评估了一家主要三级转诊中心的连续接受择期非心脏手术的患者。收集并分析了当前使用抗血小板治疗的患者的临床和生化数据。将抗血小板治疗的围手术期管理与估计的围手术期心脏风险进行了比较。
共纳入 2950 例连续患者,其中 516 例(17%)接受抗血小板治疗,主要用于治疗缺血性心脏病。289 例(56%)患者在围手术期停止了所有抗血小板治疗,包括 49%的缺血性心脏病患者和 46%的先前接受过冠状动脉支架置入术的患者。围手术期心脏风险评分并未影响抗血小板治疗管理。
约 17%的接受择期非心脏手术的患者接受抗血小板治疗,主要适应证为缺血性心脏病。近一半的先前接受过冠状动脉支架置入术的患者在围手术期没有抗血小板治疗。停止抗血小板治疗的决定很常见,但似乎并非基于围手术期心脏风险分层。